Instrument Inactif

Autres langues ISIS Pharmaceuticals, Inc. Nasdaq

Actions

US4643301090

Recherche biotechnologique et médicale

Autres langues

08/09	Royalty Pharma Shares Fall After Novartis' Pelacarsen Fails Trial
08/09	Novartis-Aktie stürzt ab - Zwei von drei großen Hoffnungsträgern gescheitert
08/09	Pharvaris' genetic disorder drug meets main goal in late-stage trial
08/09	Erneuter Fehlschlag: Novartis scheitert mit weiterem Hoffnungsträger
07/09	AKTIEN IN FOKUS: Herzmittel-Flop drückt Novartis - Auch Ionis und Amgen schwach
07/09	Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
07/09	Rückschlag bei Herzmedikament drückt Novartis-Aktie
07/09	Vielbeachtete Cholesterin-Studie von Novartis verfehlt Ziel
04/09	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- 2nd Update
04/09	Novartis, Ionis' experimental heart drug misses key goal in closely watched trial
04/09	Stocks to Watch : Ionis Pharmaceuticals, Novartis, Corvex
04/09	Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint -- Update
04/09	Ionis-Novartis heart drug misses main goal of late-stage trial
04/09	Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
04/09	Ionis Pharmaceuticals Reports Topline Results for Pelacarsen in Lp(A)Horizon Phase 3 Study
04/09	Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says
04/09	Ionis Pharmaceuticals - ZANVASTRO approved by the FDA as the first and only disease modifying treatment for Alexander disease in pediatric and adult patients
04/09	Ionis Pharmaceuticals Gets FDA Approval for Alexander Disease Treatment
04/09	Ionis Pharmaceuticals Announces FDA Approval Of Zanvastro For Treatment Of Alexander Disease In Pediatric And Adult Patients
04/09	ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
03/09	Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose
03/09	US FDA approves Ionis Pharma's therapy to treat rare genetic disorder
03/09	Ionis to present at upcoming investor conferences
03/09	Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
31/08	Trump administration to announce drug pricing deals